BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Friday, December 5, 2025
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Sep. 10, 2018
View Archived Issues
Optimized 1,4-oxazine BACE1 inhibitor shows improved safety profile in preclinical studies
Read More
When a bear spits in the woods
Read More
Microbiome metabolites and host responses
Read More
Neutrophil-lookalike membranes fight arthritis
Read More
Host changes after Zika virus infection
Read More
Carbon dioxide aggravates COPD
Read More
Different vaccination routes lead to different protection
Read More
Sichuan Kelun-Biotech Biopharmaceutical divulges MAP3K5 inhibitors
Read More
Korean researchers synthesize new LRRK2 inhibitors
Read More
Daiichi Sankyo discovers bacterial tryptophanase inhibitors
Read More
Domainex patents new IKK-E, TBK1 and SIK2 kinase inhibitors
Read More
New model of thrombopoietin receptor activation in myeloproliferative neoplams
Read More
Small-molecule CNS-penetrant autophagy enhancers suitable for study in vivo identified
Read More
Within patients, untreated metastases largely share drivers
Read More
BDD and Cingulate complete license agreement with OralogiK-enabled triple pulse products
Read More
Oryzon receives approval to initiate phase IIa REIMAGINE study of vafidemstat in aggressiveness
Read More
ZNF281 inhibits neuronal differentiation and predicts the prognosis of neuroblastoma
Read More
CureDuchenne invests in 4D Molecular Therapeutics
Read More
FDA issues complete response letter for mepolizumab in COPD
Read More
Grifols signs agreement to support research in rare and chronic diseases
Read More
Roche opens enrollment in phase III study of RO-6867461 for DME
Read More
Sareum selects SDC-1801 from TYK2 inhibitor program for advancement in autoimmune diseases
Read More
AstraZeneca initiates first-in-human study of AZD-8233
Read More